


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 6, 2006.



SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Examining Group 1632  
Patent Application  
Docket No. USF-182XC1  
Serial No. 10/655,873

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Louis D. Lieto, Ph.D.  
Art Unit : 1632  
Applicants : Shyam S. Mohapatra, Mukesh Kumar  
Serial No. : 10/655,873  
Filed : September 5, 2003  
For : Genetic Adjuvants for Immunotherapy

MS AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

11/13/2006 CNEGA1 00000004 190065 10655873  
03 FC:1806 180.00 DA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§1.97 AND 1.98


Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



Glenn P. Ladwig  
Patent Attorney  
Registration No. 46,853  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (1 page); copies of references cited therein



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
*(use as many sheets as necessary)*

Sheet

1

of

1

**Complete if Known**

Application Number	10/655,873
Filing Date	September 5, 2003
First Named Inventor	Shyam S. Mohapatra
Group Art Unit	1632
Examiner Name	Louis D. Lieto, Ph.D.

Attorney Docket Number

USF-182XC1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	GILL, D.R. et al. "The development of gene therapy for diseases of the lung" <i>Cell. Mol. Life Sci.</i> , 2004, 61:355-368.	
	R2	PERRICONE, M.A. et al. "Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium" <i>Human Gene Therapy</i> , 2001, 12:1383-1394.	
	R3	"Gene" from The American Heritage Dictionary of the English Language, 4 <sup>th</sup> Ed. (online), 2000 (retrieved on 2006-06-15). Retrieved from the Internet: <URL: <a href="http://dictionary.reference.com/browse/gene">http://dictionary.reference.com/browse/gene</a> >.	
	R4	"Timolol Maleate" from RxList The Internet Drug Index (online), 2006 (retrieved on 2006-06-15). Retrieved from the Internet: <URL: <a href="http://www.rxlist.com/cgi/generic3/timololgfs_wcp.htm">http://www.rxlist.com/cgi/generic3/timololgfs_wcp.htm</a> >.	
	R5	"Respiratory tract" from Wikipedia (online), 2006 (retrieved on 2006-06-15). Retrieved from the Internet: <URL: <a href="http://en.wikipedia.org/wiki/Respiratory_tract">http://en.wikipedia.org/wiki/Respiratory_tract</a> >.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.